Nick Webb
@profnickwebb.bsky.social
Paediatric nephrologist
VP Medical Affairs / Clinical Development at Sobi Basel 🇨🇭
Anti-complement therapy for rare kidney disease
🏃 and ⛷️and COYS
VP Medical Affairs / Clinical Development at Sobi Basel 🇨🇭
Anti-complement therapy for rare kidney disease
🏃 and ⛷️and COYS
Reposted by Nick Webb
📣Excited to share with the #nephrology community the latest updates in #C3G and primary #ICMPGN clinical trials at #ERA25. If you are a healthcare professional, do not miss the late breaking session: Innovative Kidney Trials at ⏲️15:00 at the Square #nephrology #kidneydisease
June 6, 2025 at 1:04 PM
📣Excited to share with the #nephrology community the latest updates in #C3G and primary #ICMPGN clinical trials at #ERA25. If you are a healthcare professional, do not miss the late breaking session: Innovative Kidney Trials at ⏲️15:00 at the Square #nephrology #kidneydisease
Reposted by Nick Webb
We are excited to be at #ERA25 in sunny Vienna🔅. If you are a healthcare professional join us at booth X3.110 to meet the #Sobi team and learn more about #C3G #IC-MPGN #complement #Rare_Sobi #Sobi_nephrology
June 4, 2025 at 12:34 PM
We are excited to be at #ERA25 in sunny Vienna🔅. If you are a healthcare professional join us at booth X3.110 to meet the #Sobi team and learn more about #C3G #IC-MPGN #complement #Rare_Sobi #Sobi_nephrology
Reposted by Nick Webb
📣 Save the date! Our symposium at #ERA25, where we will explore the power of #complement inhibition in #C3G and primary #ICMPGN, join Prof Marina Vivarelli, Prof. Matthew Pickering and Prof. Fadi Fakhouri on 🗓️ June 6, 🕙 10:00-11:00 (CEST) in Hall B
June 4, 2025 at 3:31 PM
📣 Save the date! Our symposium at #ERA25, where we will explore the power of #complement inhibition in #C3G and primary #ICMPGN, join Prof Marina Vivarelli, Prof. Matthew Pickering and Prof. Fadi Fakhouri on 🗓️ June 6, 🕙 10:00-11:00 (CEST) in Hall B
Reposted by Nick Webb
Findings on the Sparsentan study: A New Dawn for IgA Nephropathy.
⬇️ Download the visual abstract: www.theisn.org/wp-co...
📽️ Watch the industry webinar: academy.theisn.org/p...
Supported by @travererare.bsky.social
⬇️ Download the visual abstract: www.theisn.org/wp-co...
📽️ Watch the industry webinar: academy.theisn.org/p...
Supported by @travererare.bsky.social
April 4, 2025 at 12:00 PM
Findings on the Sparsentan study: A New Dawn for IgA Nephropathy.
⬇️ Download the visual abstract: www.theisn.org/wp-co...
📽️ Watch the industry webinar: academy.theisn.org/p...
Supported by @travererare.bsky.social
⬇️ Download the visual abstract: www.theisn.org/wp-co...
📽️ Watch the industry webinar: academy.theisn.org/p...
Supported by @travererare.bsky.social
Reposted by Nick Webb
@kidneydoc101.bsky.social is the President Elect of the @theisn.org ! Honoured to call this exceptional woman and Leader my friend and colleague, and look forward to her vibrant contributions to #Kidneyhealth
February 16, 2025 at 10:51 AM
@kidneydoc101.bsky.social is the President Elect of the @theisn.org ! Honoured to call this exceptional woman and Leader my friend and colleague, and look forward to her vibrant contributions to #Kidneyhealth
Reposted by Nick Webb
Sparsentan for FSGS isn’t dead yet… ir.travere.com/news-release...
ir.travere.com
February 12, 2025 at 1:13 PM
Sparsentan for FSGS isn’t dead yet… ir.travere.com/news-release...
Reposted by Nick Webb
Join the @theisn.org ! 🌍
We continue our mission in advancing kidney care! The SoMe team is enjoying the #ISNWCN #MedSky #NephSky
We continue our mission in advancing kidney care! The SoMe team is enjoying the #ISNWCN #MedSky #NephSky
February 7, 2025 at 10:55 AM
Join the @theisn.org ! 🌍
We continue our mission in advancing kidney care! The SoMe team is enjoying the #ISNWCN #MedSky #NephSky
We continue our mission in advancing kidney care! The SoMe team is enjoying the #ISNWCN #MedSky #NephSky
Reposted by Nick Webb
Reposted by Nick Webb
The 2024 USRDS report is out (a few weeks ago actually)
usrds-adr.niddk.nih.gov/2024
It’s a treasure trove of data for nephrology nerds, aka all of #NephSky
So, short 🧶 on ESRD incidence/prevalence
usrds-adr.niddk.nih.gov/2024
It’s a treasure trove of data for nephrology nerds, aka all of #NephSky
So, short 🧶 on ESRD incidence/prevalence
Annual Data Report | USRDS
Unites States Renal Data System Annual Data Report
usrds-adr.niddk.nih.gov
November 17, 2024 at 1:37 AM
The 2024 USRDS report is out (a few weeks ago actually)
usrds-adr.niddk.nih.gov/2024
It’s a treasure trove of data for nephrology nerds, aka all of #NephSky
So, short 🧶 on ESRD incidence/prevalence
usrds-adr.niddk.nih.gov/2024
It’s a treasure trove of data for nephrology nerds, aka all of #NephSky
So, short 🧶 on ESRD incidence/prevalence
Reposted by Nick Webb
The phase 3 VALIANT trial has been evaluating the drug, pegcetacoplan, in patients with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). pmlive.com/pharma_news/... #kidneyhealth
Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study - PMLiVE
There are currently no treatments that target the underlying cause of C3G or IC-MPGN
pmlive.com
August 14, 2024 at 3:37 PM
The phase 3 VALIANT trial has been evaluating the drug, pegcetacoplan, in patients with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). pmlive.com/pharma_news/... #kidneyhealth
Reposted by Nick Webb
November 14, 2024 at 10:25 AM